Global Thyroid Eye Disease Treatment Market (2025 Edition): Analysis By Therapeutic Type (Monoclonal Antibodies, Corticosteroids, Vitamins, and Other Therapies), Route of Administration, Distribution Channel: Market Insights and Forecast (2021-2031)

Executive Summary

Azoth Analytics has released a research report titled “Global Thyroid Eye Disease Treatment Market (2025 Edition)” which provides a complete analysis of the Global Thyroid Eye Disease Treatment industry in terms of market segmentation By Therapeutic Type (Monoclonal Antibodies, Corticosteroids, Vitamins, and Other Therapies), By Route of Administration (Oral, Parenteral, and Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Channel) for the historical period of 2021-2024, the estimates of 2025 and the forecast period of 2026-2031.

The report analyses the Thyroid Eye Disease Treatment Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom, France, Germany, Italy, Spain, China, Japan, and India). The Global Thyroid Eye Disease Treatment market showcased growth at a CAGR of 9.47% during 2021-2024. The market was valued at USD 4.53 Billion in 2024 which is expected to reach USD 11.81 Billion in 2031. The global market for Thyroid Eye Diseases is seeing substantial expansion and demonstrating an exponential rise. The market is influenced by various factors, including technological improvements and the increasing prevalence of hyperthyroidism and hypothyroidism.

The primary driver of the global thyroid eye disease (TED) treatment market is the increasing prevalence of Graves' disease and thyroid disorders. As TED is commonly associated with Graves' disease, the rising incidence of hyperthyroidism significantly boosts the demand for treatment options. Additionally, growing awareness and early diagnosis have led to higher adoption rates of targeted therapies, supported by advancements in diagnostic technologies such as MRI and CT scans.

Firstly, advancements in therapeutic approaches and increased awareness and knowledge about Thyroid Eye Disease (TED) contribute to the market's expansion. New and improved treatment options are expected to enhance patient outcomes and drive market growth. Secondly, the expansion of medical infrastructure in emerging economies is playing a vital role in driving the Thyroid Eye Disease market. As healthcare systems and facilities improve in these regions, more individuals can access diagnosis and treatment for TED, leading to market growth.

Additionally, the high prevalence of TED, ranging from 25% to 50% among individuals with Graves' disease and the ability of TED to manifest independently of Graves' disease, significantly contribute to market expansion. This widespread occurrence of the condition creates a substantial patient pool and market demand. Furthermore, epidemiological studies indicating an annual incidence rate of 16 cases per 100,000 women and 2.9 cases per 100,000 men in the general population highlight the need for effective treatments, driving the market forward.

Individuals experiencing severe Thyroid Eye Disease (TED), resulting in significant vision impairments and reduced overall quality of life, are more likely to seek medical intervention. This growing demand for various treatment options, including innovative therapies such as monoclonal antibodies and surgical procedures, has the potential to drive market expansion.

Autoimmune disorders can be influenced by environmental factors, including exposure to pollution, chemicals, and radiation. In some developing countries, like India and China, where environmental controls and pollution regulations are inadequate, the risk of developing Thyroid Eye Disease may be elevated.

Moreover, changes in lifestyle and dietary habits, such as increased consumption of processed foods, reduced physical activity, and elevated stress levels, can lead to hormone imbalances. These lifestyle modifications can contribute to a higher incidence of thyroid-related conditions, often linked to Thyroid Eye Disease, further fueling market demand.

The management of Thyroid Eye Disease has undergone a significant transformation, shifting away from conservative methods such as monitoring and surgery in favor of targeted biologic therapies. This shift emphasizes the enhancement of cosmetic outcomes and the improvement of patients' quality of life, positively impacting market dynamics.

Advancements in surgical techniques have also led to improved treatment outcomes while significantly reducing the risk of complications. The proliferation of treatments for the active phase of the disease has had a substantial impact on the quality of life of individuals affected by this condition.

Scope of the Report:

• The report analyses the Thyroid Eye Disease Treatment Market by Value (USD Million).
• The report analyses the Thyroid Eye Disease Treatment Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom, France, Germany, Italy, Spain, China, Japan, and India).
• The report presents the analysis of Thyroid Eye Disease Treatment Market for the historical period of 2021-2024, the estimated year 2025 and the forecast period of 2026-2031.
• The report analyses the Thyroid Eye Disease Treatment Market by Therapeutic Type (Monoclonal Antibodies, Corticosteroids, Vitamins, and Other Therapies).
• The report analyses the Thyroid Eye Disease Treatment Market by Route of Administration (Oral, Parenteral, and Topical).
• The report analyses the Thyroid Eye Disease Treatment Market by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Channel).
• The key insights of the report have been presented through the frameworks of SWOT. Also, the attractiveness of the market has been presented by region, by therapeutic type, by route of administration, & by distribution channel.
• Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analyzed in the report are Amgen, Viridian therapeutics, Novartis AG, Roche holding AG, Sanofi, AbbVie Inc., and Teva Pharmaceutical.